文拉法新和西肽普兰治疗精神分裂症阴性症状的临床观察

目的:观察西肽普兰和文拉法新合并抗精神病药物治疗精神分裂症阴性症状的疗效和不良反应。方法:精神分裂症患者80例,随机分为文拉法新组和西肽普兰组各40例,分别给予文拉法新或西肽普兰治疗12周,在治疗前和治疗后第4、8、12周以阳性症状和阴性症状量表(PANSS)和不良反应量表(TESS)评定疗效和不良反应。结果:治疗12周文拉法新组阴性因子分减分率显著高于西肽普兰组(P<0.01),阴性因子症状评分低于西肽普兰组(P<0.05)。文拉法新组胃肠道不良反应发生率与西肽普兰组比较有差异(P<0.05)。结论:西肽普兰和文拉法新治疗精神分裂症的阴性症状安全有效,协同抗精神病药物治疗精神分裂症可增加疗效,文拉法新略优于西肽普兰。

A Comparative Study of Venlafaxine and Citalopram on Treatment of Negative Symptoms of Schizophrenia

Objective: To investigate the efficacy and side effects of venlafaxine and citalopram in combination with risperidone on the treatment of negative symptoms of schizophrenia.Methods: Eighty schizophrenic patients with negative symptoms were randomly divided into venlafaxine group and citalopram group.The efficacy and side effects were assessed with the Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Symptoms Scale(TESS) respectively before and 4,8,12 weeks after treatment.Results: The reduction of PANSS score on negative symptoms in venlafaxine group at week 12 were significantly higher than that of the citalopram group(P<0.01).There was a significant difference in the TESS scores of gastrointestinal tract between the two groups.Conclusion: The study suggests that citalopram and venlafaxine in combination with typical antipsychotics were effective and safe in treating negative symptoms of schizophrenic patients.